Tacrolimus time in therapeutic range and long‐term outcomes in heart transplant recipients

Abstract

Study ObjectiveLittle is known about the association between tacrolimus time in therapeutic range (TTR) within the guideline‐recommended targets and heart transplant (HT) patient outcomes. This study evaluated the association of early tacrolimus TTR with rejection and other clinical outcomes during an extended follow‐up after HT.DesignThis was a single‐center retrospective cohort study.SettingThe study was conducted at Michigan Medicine (1/1/2006–12/31/2017).PatientsHT recipients ≥18 years of age were included.MeasurementThe primary end point was the effect of tacrolimus TTR on time to rejection over the entire follow‐up period.Main ResultsA total of 137 patients were included with a median follow‐up of 53 months. Based on the median TTR of 58%, the patients were divided into the low tacrolimus TTR (n = 68) and high tacrolimus TTR (n = 69) cohort. The high tacrolimus TTR was associated with a significantly lower risk of rejection compared to the low tacrolimus TTR cohort (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41–0.98; p = 0.04). A post hoc analysis revealed associations between rejection and TTR when high and low TTR groups were created at different levels. TTR <30% was associated with a 7‐fold higher risk of rejection (HR 7.56; 95% CI 1.76–37.6; p < 0.01) and TTR >75% was associated with a 77% lower risk of rejection (HR 0.23; 95% CI 0.08–0.627; p < 0.01).ConclusionsPatients in the higher tacrolimus TTR cohort had a lower risk of rejection. We observed correlations between higher risk of rejection with TTR <30% and lower risk of rejection with TTR >75%. Future studies should focus on validating the optimal TTR cutoff while also exploring a cutoff to delineate high‐risk patients for which early interventions to improve tacrolimus TTR may be beneficial.